摘要
重症肌无力（MG）是一种累及神经肌肉接头的获得性自身免疫性疾病，目前绝大多数MG患者经传统治疗（乙酰胆碱酯酶抑制剂、血浆置换、丙球、免疫抑制剂等）后，预后有了明显改善，但仍有一小部分患者为难治性MG，尚未得到有效的治疗，预后较差。最近研究提示一些新型免疫调节剂、二次胸腺扩大清除术、造血干细胞移植可能对其有效。
Myasthenia gravis is an autoimmune disease involving the acquired neuromuscular junction. Vast majority of patients with myasthenia gravis after conventional treatment （acetylcholinesterase inhibitors, plasmapheresis, gammaglobulin, and immunosuppressants） has significantly improved prognosis; but, there is still a small portion of patients had refractory myasthenia gravis, they did not have effective treatment, and their prognosis is poor. Some recent studies suggest that novel immunomodulatory agents, secondary thymus expand dissection, hematopoietic stem cell transplantation may be in force.
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2016年第3期319-321,共3页
Chinese Journal of Neuromedicine
关键词
重症肌无力
难治性
治疗
Myasthenia gravis
Refractory
Treatment
